BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. filed an initial ownership report for Susan E. Atkins, identifying her as a director of the company. The filing does not report any equity transactions or holdings and notes an exhibit consisting of a Power of Attorney authorizing SEC filing-related actions.

Key Terms

Form 3, beneficial ownership, Power of Attorney

3 terms

Form 3 regulatory

"BioXcel Therapeutics, Inc. filed an initial ownership report on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"It serves as her initial beneficial ownership report but does not list holdings"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Power of Attorney regulatory

"remarks section references Exhibit 24 - Power of Attorney authorizing actions"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

What does the Form 3 for BTAI disclose about Susan E. Atkins?

The Form 3 identifies Susan E. Atkins as a director of BioXcel Therapeutics, Inc. It serves as her initial beneficial ownership report but does not list any specific share holdings or transactions.

Are any stock transactions reported for Susan E. Atkins in BTAI's Form 3?

No. The Form 3 for Susan E. Atkins shows no reported transactions, with zero buy, sell, acquire, dispose, or derivative entries in the transaction summary data provided.

Does the BTAI Form 3 mention a Rule 10b5-1 trading plan for Susan E. Atkins?

No. The Rule 10b5-1 indicator is null, meaning the filing does not state that any reported activity (there is none) occurred under a Rule 10b5-1 trading plan or similar arrangement.

What exhibit is referenced in Susan E. Atkins’s Form 3 for BTAI?

The remarks section references an exhibit titled Exhibit 24 - Power of Attorney, indicating that a power of attorney has been filed to authorize certain individuals to act on filing-related matters.

Is Susan E. Atkins a 10% owner of BioXcel Therapeutics (BTAI) according to the Form 3?

No. The reporting-person data marks her as a director and explicitly indicates she is not a ten percent owner, with that status flag set to zero.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/14/2026 - 07:00 PM Accepted by SEC EDGAR 08/14/2026 - 07:00 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Atkins Susan E.

(Last) (First) (Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN CONNECTICUT 06511

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/12/2026

3. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Javier Rodriguez, Attorney-in-Fact for Susan E. Atkins	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)